{"entity":{"id":"nct07743112","kind":"trial","name":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","aka":[],"tldr":"A phase 2 trial of Azacitidine and Venetoclax in acute myeloid leukaemia, run by Maxinovel Pty., Ltd., now recruiting.","summary":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia is a phase 2 interventional study registered as NCT07743112 by Maxinovel Pty., Ltd., with 43 participants planned, started 2025-09-05 and due to reach its primary completion in 2027-09-01. Interventions recorded: MAX-40279, Azacitidine and Venetoclax.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07743112","url":"https://clinicaltrials.gov/study/NCT07743112"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","aml-older-unfit"],"sections":[],"technologies":["bcl2-inhibitors","cytotoxic-chemotherapy","epigenetic-drugs","kinase-inhibitors"],"targets":[],"drugs":["azacitidine","venetoclax"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07743112","phase":"2","setting":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","sponsor":"Maxinovel Pty., Ltd.","started":"2025-09-05","startedType":"actual","enrolled":43,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07743112/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}]}}